Ig - Look at it this way: Just because any company starts a clinical trial, that doesn't legally require them to finish it. Any number of things can and do change during the many years a clinical trial is active.
If ADXS doesn't want to finish the trial, I believe there will be a way out. How partners like Stendhal are handled would be defined in the ADXS-Stendhal agreement. There's probably an old SEC filing that speaks to the situation you're discussing.
I work on buy-side contracts and I haven't a clue on what be standard terms for a bio partnership agreement. I'd have to think those that represented adxs in the negotiations contemplated an out for either convenience or cause with a possible penalty or some other agreed upon solution. It's way too risky to go into an agreement without an exit clause for them.
News 
Market Data 
Discover 
AI
